Survey 1: Demographic Survey

Thank you for participating in the Extension for Community Healthcare Outcomes (ECHO) Project Biosafety Community of Practice sessions facilitated by the Division of Laboratory Systems, Centers for Disease Control and Prevention. To better understand the audience for these sessions, we are conducting this voluntary survey of all attendees.

Survey questions will take no more than 1 minute to complete. Your responses will be anonymous, and no unique identifying information will be sought or kept. The feedback we receive will be summarized in aggregate only and used for program improvement. If you encounter issues with this evaluation, please email dlsbiosafety@cdc.gov

CDC estimates the average public reporting burden for this collection of information as 1 minute per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1050).

Please click "next" to begin the survey.

Public Health Laboratory	
Hospital (Clinical) Laboratory	
Commercial/Private Laboratory	
Point-of-Care Testing Site	
University	
Other	
2. What is your current role?	
Laboratory Director	
Quality Manager	
Biosafety Officer/Professional	
Laboratory Technician	
Other	

1. What type of facility do you work in?

3.	How many years have you been performing in this role?
	0-2 years
	3-5 years
	>5 years
4.	How many personnel work within your facility?
	Less than 25
	25-50
	More than 50
5.	Do you have a dedicated personnel for biosafety? Select all that apply.
	Biosafety
	Quality Management
	None of the above

CDC DLS	
APHL workgroups or committees	
Coworker/Colleague	
ABSA	
Other, please specify:	

6. How did you hear about this training? (Select all that apply)

We thank you for your time spent taking this survey. Your response has been recorded.

Form Approved OMB Control No. 0920-1050 Exp. Date: 06/30/2025

Survey 2: 2025 ECHO Post-Session Survey Questions

Thank you for taking this voluntary survey to help us understand to what extent the ECHO Biosafety Community of Practice sessions facilitated by the Division of Laboratory Systems, Centers for Disease Control and Prevention have been serving the needs of the participants. The feedback you provide will also inform future session development.

Survey questions will take no more than 2 minutes to complete. Your responses will be anonymous, and no unique identifying information will be sought or kept. The feedback we receive will be summarized in aggregate only and used for program improvement. If you encounter issues with this evaluation, please email dlsbiosafety@cdc.gov

CDC estimates the average public reporting burden for this collection of information as 2 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1050).

Please click "next" to begin the survey.

Thank you for attending the [Session Title] ECHO Biosafety Session on [Session Date]. Please respond to the following question about this session.

1. To what extent do you agree with the following statements:

	Agree	Neither/Undecided	Disagree
Content was relevant to my current work	0	0	0
Session addressed a gap in my understanding of the topic	0	0	0
Session improved my knowledge level	0	0	0
Speaker was knowledgeable	0	0	0
Speaker was organized and communicated clearly	0	0	0
Session materials supported content	0	0	0
Session learning objectives were clear	0	0	0
Session had the right balance of lecture and interactivity	0	0	0
Session length was appropriate	0	0	0
Session pace was appropriate	0	0	0
The session was well planned and organized	0	0	0
Case study presented was useful	0	0	0
Difficulty level of case study was appropriate	0	0	0
Overall, I was satisfied with the session	0	0	0
I am likely to recommend this session to others	0	0	0

Definitely not
Probably not
Possibly
Probably yes
Definitely yes
Not applicable – I did not learn anything new from this session
. What factors will keep you from using the content of this session in your work? (Select all nat apply)
I need additional training in the subject matter
I will not have the resources or opportunities to use what I learned
I will not have the time to use what I learned
My supervisor or colleagues will not support me in using what I learned
The session content is not relevant to my current work
Other, please specify:

2. Will you use what you learned in this session in your work?

5. What part of this session was most helpful to your learning?
6. How could this session be improved?

We thank you for your time spent taking this survey. Your response has been recorded.

Form Approved OMB Control No. 0920-1050 Exp. Date: 06/30/2025

Survey 3: CDC Biosafety ECHO Follow-up Surveys

Thank you for taking this voluntary survey to help us understand to what extent the ECHO Biosafety Community of Practice sessions facilitated by the Division of Laboratory Systems, Centers for Disease Control and Prevention have been serving the needs of the participants. This survey asks for your feedback on the past 6 sessions. Your answers are vital to ensure the sessions are meeting your needs and understanding additional supports needed. The feedback you provide will also inform future session development.

Survey questions will take no more than 2 minutes to complete. Your responses will be anonymous, and no unique identifying information will be sought or kept. The feedback we receive will be summarized in aggregate only and used for program improvement. If you have any questions, please email dlsbiosafety@cdc.gov.

CDC estimates the average public reporting burden for this collection of information as 2 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1050).

Please click "next" to begin the survey.

1. Which ECHO Biosafety session(s) did you attend in the past six months? Select all that apply

The Importance of Laboratory Design for Effective Biosafety Operations (January 2025)

Building a Culture of Safety: Experiences and Best Practices from the North Carolina State Laboratory (February 2025)

From Bench to Safety: Implementing Effective Laboratory Practices in Clinical Microbiology (March 2025)

Update on ISO 35001 Implementation in NH PHL – Biosafety Plan Updates (April 2025)

Advancing Public Health Through Effective Laboratory Management and Microbiological Testing (May 2025)

Advancing safe practices in high-containment laboratories (June 2025)

I have not attended any of these ECHO Biosafety sessions

1. Which ECHO Biosafety session(s) did you attend in the past six months? Select all that apply

Best Practices in Biosafety and Biosecurity for Bioterrorism Response (July 2025)

Artificial Intelligence in Biosafety: Revolutionizing Laboratory Safety and Compliance (August 2025)

Building an Integrated Biosafety and Biosecurity Strategy: Challenges and Innovations (September 2025)

Equity in Biosafety (October 2025)

Informatics Safety in the Laboratory (November 2025)

Biosafety Training and Outreach to Clinical Laboratories (December 2025)

I have not attended any of these ECHO Biosafety sessions

2. Select all that apply for each session attended.

After participating in this session, in my personal or facility's work practices:

	I used information from this session to identify biosafety areas for improvement	I can discuss biosafety challenges I encounter	I feel empowered to communicate acquired laboratory safety knowledge	I reviewed the current processes and procedures to determine if they are up to date
The Importance of Laboratory Design for Effective Biosafety Operations (January 2025)				
Building a Culture of Safety: Experiences and Best Practices from the North Carolina State Laboratory (February 2025)				
From Bench to Safety: Implementing Effective Laboratory Practices in Clinical Microbiology (March 2025)				
Update on ISO 35001 Implementation in NH PHL – Biosafety Plan Updates (April 2025)				
Advancing Public Health Through Effective Laboratory Management and Microbiological Testing (May 2025)				
Advancing safe practices in high-containment laboratories (June 2025)				

2. Select all that apply for each session attended.

After participating in this session, in my personal or facility's work practices:

	I used information from this session to identify biosafety areas for improvement	I can discuss biosafety challenges I encounter	I feel empowered to communicate acquired laboratory safety knowledge	I reviewed the current processes and procedures to determine if they are up to date
Best Practices in Biosafety and Biosecurity for Bioterrorism Response (July 2025)				
Artificial Intelligence in Biosafety: Revolutionizing Laboratory Safety and Compliance (August 2025)				
Building an Integrated Biosafety and Biosecurity Strategy: Challenges and Innovations (September 2025)				
Equity in Biosafety (October 2025)				
Informatics Safety in the Laboratory (November 2025)				
Biosafety Training and Outreach to Clinical Laboratories (December 2025)				

work? (Select all that apply)

Training in the subject matter

Availability of resources or opportunities to use what I learned

Time to use what I learned

Supervisors or colleagues supported me in using what I learned

Relevance to my current work

Other (please specify)

Not applicable

3. What factors facilitated your use of the content from the session(s) you attended in your

work? (Select all that apply)
I need additional training in the subject matter
Lack of resources or opportunities to use what I learned
Lack of time to use what I learned
My supervisor or colleagues will not support me in using what I learned
The course content was not relevant to my current work
Other (please specify)
Not applicable
5. Would you like to stay connected with this Biosafety Community of Practice (participants and/or speakers) in the future?
Yes
No
6. What suggestions do you have to enhance members' engagement after the Biosafety Community of Practice sessions end?

4. What factors impeded your use of the content from the session(s) you attended in your

We thank you for your time spent taking this survey. Your response has been recorded.